Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Mahé, Isabelle ^a   Sterpu, Raluca ^b   Bertoletti, Laurent ^c   López Jiménez, Luciano ^d   Joan, Meritxell Mellado ^e   Trujillo Santos, Javier ^f   Ballaz, Aitor ^g   Hernández Blasco, Luis Manuel ^h   Marchena, Pablo Javier ⁱ   Monreal, Manuel ^j   Ameneiro, E ^f   Arcelus, J I ^f   Ballaz, A ^f   Barba, R ^f   Barron M ^f   Barron Andres B ^f   Bascunana J ^f   Blanco Molina, A ^f   Bueso, T ^f   Casado, I ^f   Conget, F ^f   Del Molino, F ^f   Del Toro, J ^f   Falga C ^f   Fernandez Capitan C ^f   Font, L ^f   Fuentes, M I ^f   Gallego, P ^f   Garcia Bragado F ^f   Garcia Lorenzo M D ^f   Gomez V ^f   Gonzalez J ^f   Gonzalez Bachs E ^f   Guil, M ^f   Gutierrez J ^f   Hernandez L ^f   Hernandez Huerta S ^f   Jaras, M J ^f   Jimenez D ^f   Lecumberri, R ^f   Lobo, J L ^f   Lopez Jimenez L ^f   Lopez Montes L ^f   Lopez Reyes R ^f   Lopez Saez J B ^f   Lorente, M A ^f   Lorenzo, A ^f   Luque, J M ^f   Madridano, O ^f   Marchena, P J ^f   Martin M ^f   Mellado, M ^f   Monreal, M ^f   Mora, J M ^f   Nauffal, D ^f   Nieto, J A ^f   Nunez M J ^f   Ogea, J L ^f   Paul, H ^f   Pedrajas, J M ^f   Peris, M L ^f   Porras, J A ^f   Riera Mestre, A ^f   Rivas, A ^f   Rodriguez Davila M A ^f   Roman P ^f   Rosa, V ^f   Ruiz Gimenez N ^f   Ruiz, J ^f   Sahuquillo, J C ^f   Samperiz, A ^f   Sanchez R ^f   Sanchez Munoz Torrero J F ^f   Soler, S ^f   Surinach J M ^f   Tiberio, G ^f   Tilvan R M ^f   Tolosa, C ^f   Trujillo Santos, J ^f   Uresandi, F ^f   Valdes M ^f   Valero, B ^f   Valle, R ^f   Vela, J ^f   Vidal, G ^f   Vilella, V ^f   Villalta, J ^f   Verhamme, P ^f   Peerlinck, K ^f   Wells, P ^f   Maly R ^f   Hirmerova, J ^f   Kaletova, M ^f   Bertoletti, L ^f   Bura Riviere, A ^f   Farge Bancel, D ^f   Hij, A ^f   Mahe, I ^f   Merah, A ^f   Schellong, S ^f   Babalis, D ^f   Papadakis, M ^f   Tzinieris, I ^f   Braester, A ^f   Brenner, B ^f   Tzoran, I ^f   Zeltser, D ^f   Amitrano, M ^f   Apollonio, A ^f   Barillari, G ^f   Ciammaichella, M ^f   Dalla Valle, F ^f   Di Micco, P ^f   Duce, R ^f   Guida, A ^f   Maida, R ^f   Pasca, S ^f   Piovella, C ^f   Prandoni, P ^f   Rota, L ^f   Tiraferri, E ^f   Tonello, D ^f   Tufano, A ^f   Visona A ^f   Zalunardo, B ^f   Brinquinho, M ^f   Miranda, D ^f   Sousa, M S ^f   Bosevski, M ^f   Kovacevic, D ^f   Alatri, A ^f   Bounameaux, H ^f   Calanca, L ^f   Mazzolai, L ^f   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c HÔPITAL NORD   (France)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f Complejo Hospitalario Universitario de Cartagena ^*  (Switzerland)

^g HOSPITAL DE GALDAKAO   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁱ HOSPITAL GENERAL DE CATALUNYA   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; FONDAPARINUX; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP;

ADULT; AGE; AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CANCER PATIENT; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DISEASE REGISTRY; DRUG CHOICE; FEMALE; HUMAN; IMMOBILITY; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METASTASIS; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PRACTICE GUIDELINE; RISK FACTOR; SEX DIFFERENCE; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; COMPLICATION; FOLLOW UP; NEOPLASM; PRESCRIPTION; PROTOCOL COMPLIANCE; STATISTICS AND NUMERICAL DATA; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG PRESCRIPTIONS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84953897284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128741     Document Type: Article

References (20)

1. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al American College of Chest Physicians. American College of Chest Physicians. Antithrombotic Therapy for VTE Disease. Antithrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e419S-494S doi: 10.1378/chest.11-2301 PMID: 22315268
2. Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, et al. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients: findings from the RIETE registry. J Thromb Haemost. 2004; 2: 1892-1898. PMID: 15550017
3. Laporte S, Mismetti P, Décousus H, Uresandi F, Otero R, Lobo JL, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism; Findings from the registro informatizado de la enfermedad tromboembólica venosa (RIETE) Registry. Circulation. 2008; 117: 1711-1716. doi: 10.1161/CIRCULATIONAHA.107.726232 PMID: 18347212
4. Sánchez Muñoz-Torrero JF, Bounameaux H, Pedrajas JM, Lorenzo A, Rubio S, Kearon C, et al. Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. J Vasc Surg. 2011; 54(6 Suppl): 26S-32S. doi: 10.1016/j.jvs.2011.05.114 PMID: 21908150
5. Trujillo-Santos J, Schellong S, Falga C, Zorrilla V, Gallego P, Barrón M, et al. Low-molecular-weight or unfractionated heparin in venous thromboembolism: The influence of renal function. Am J Med. 2013; 126: 425-434. doi: 10.1016/j.amjmed.2012.09.021 PMID: 23499331
6. Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008; 100: 26-31. doi: 10.1160/TH08-03-0193 PMID: 18612534
7. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 349: 631-639. PMID: 12917299
8. Rahme E, Feugère G, Sirois C, Weicker S, Ramos E. Anticoagulant use in patients with cancer associated venous thromboembolism: A retrospective cohort study. Thromb Res. 2013; 131: 210-217. doi: 10.1016/j.thromres.2012.12.004 PMID: 23290095
9. Monreal M, Falgá C, Valdés M, Suárez C, Gabriel F, Tolosa C, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: Findings from the RIETE Registry. J Thromb Haemost. 2006; 4: 1950-1956. PMID: 16961602
10. Palareti G, Cosmi B. Bleeding with anticoagulation therapy-Who is at risk, and how best to identify such patients? Thromb Haemost. 2009; 102: 268-278. doi: 10.1160/TH08-11-0730 PMID: 19652877
11. Sánchez Muñoz-Torrero JF, Bounameaux H, Pedrajas JM, Lorenzo A, Rubio S, Kearon C, et al. Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. J Vasc Surg. 2011; 54: 26S-32S. doi: 10.1016/j.jvs.2011.05.114 PMID: 21908150
12. Cohen AT, Imfeld S, Rider T. Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther. 2014; 31: 473-493. doi: 10.1007/s12325-014-0119-7 PMID: 24821599
13. Kahn SR, Springmann V, Schulman S, Martineau J, Stewart JA, Komari N, et al. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. Thromb Haemost. 2012; 108: 493-498. doi: 10.1160/TH12-03-0169 PMID: 22782073
14. Caprini JA, Tapson VF, Hyers TM, Waldo AL, Wittkowsky AK, Friedman R, et al NABOR Steering Committee. Treatment of venous thromboembolism: Adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg. 2005; 42: 726-733. PMID: 16242561
15. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med. 2002; 162: 1729-1735. PMID: 12153376
16. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al CLOT Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349: 146-153. PMID: 12853587
17. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119: 1062-1072. PMID: 17145251
18. Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, et al. Outpatient Use of Low Molecular Weight Heparin Monotherapy for First-Line Treatment of Venous Thromboembolism in Advanced Cancer. Oncologist. 2012; 17:419-427. doi: 10.1634/theoncologist.2011-0323 PMID: 22334451
19. Tapson V, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007; 132: 936-945. PMID: 17573514
20. Bergmann JF, Cohen AT, Tapson VF, Goldhaber SZ, Kakkar AK, Deslandes B, et al.; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost. 2010; 103: 736-748. doi: 10.1160/TH09-09-0667 PMID: 20135072